[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2023000028A - Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos - Google Patents

Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos

Info

Publication number
DOP2023000028A
DOP2023000028A DO2023000028A DO2023000028A DOP2023000028A DO P2023000028 A DOP2023000028 A DO P2023000028A DO 2023000028 A DO2023000028 A DO 2023000028A DO 2023000028 A DO2023000028 A DO 2023000028A DO P2023000028 A DOP2023000028 A DO P2023000028A
Authority
DO
Dominican Republic
Prior art keywords
heteroaryl
derivatives
pharmaceutical uses
substituted spiropiperidinyl
spiropiperidinyl
Prior art date
Application number
DO2023000028A
Other languages
English (en)
Inventor
Chen Xin
Thoma Gebhard
LABBE-GIGUERE Nancy
Bushaboina Mallesh
Kim Cheung Atwood
James Culshaw Andrew
Miltz Wolfgang
Orain David
Patel Tajesh
Rajagopalan Srinivasan
Roehn Till
Andrew Sandham David
Bhanudasji Tichkule Ritesh
Wälchli Rudolf
Brian Hurley Timothy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DOP2023000028A publication Critical patent/DOP2023000028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo; (I) en donde R1 R2, R4 y X1 han sido definidos en la presente, a un método de elaboración de los compuestos de la invención, y a sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
DO2023000028A 2020-08-14 2023-02-10 Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos DOP2023000028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20191191 2020-08-14
PCT/IB2021/057427 WO2022034529A1 (en) 2020-08-14 2021-08-12 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
DOP2023000028A true DOP2023000028A (es) 2023-03-15

Family

ID=72088005

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000028A DOP2023000028A (es) 2020-08-14 2023-02-10 Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos

Country Status (21)

Country Link
US (2) US11708366B2 (es)
EP (1) EP4196478A1 (es)
JP (2) JP7545570B2 (es)
KR (1) KR20230051227A (es)
CN (1) CN116157404A (es)
AR (1) AR123241A1 (es)
AU (2) AU2021325431B2 (es)
BR (1) BR112023002031A2 (es)
CA (1) CA3185469A1 (es)
CL (1) CL2023000418A1 (es)
CO (1) CO2023002940A2 (es)
CR (1) CR20230125A (es)
DO (1) DOP2023000028A (es)
EC (1) ECSP23017158A (es)
IL (1) IL299091A (es)
MX (1) MX2023001725A (es)
PE (1) PE20230855A1 (es)
SA (1) SA523442503B1 (es)
TW (1) TW202220990A (es)
UY (1) UY39377A (es)
WO (1) WO2022034529A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7545570B2 (ja) * 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998834A (en) 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2003028732A1 (fr) 2001-09-28 2003-04-10 Kyowa Hakko Kogyo Co., Ltd. Antagoniste de recepteur
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
EP2185504A2 (en) 2007-09-04 2010-05-19 Biolipox AB Bis-aromatic compounds useful in the treatment of inflammation
WO2011110824A1 (en) * 2010-03-12 2011-09-15 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
JP2013515033A (ja) 2009-12-21 2013-05-02 ノバルティス アーゲー オレキシン受容体アンタゴニストとしてのジアザ−スピロ［５．５］ウンデカン類
NZ605988A (en) 2010-06-23 2014-11-28 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
KR20130099040A (ko) 2010-08-10 2013-09-05 셀진 아빌로믹스 리서치, 인코포레이티드 Ｂｔｋ 억제제의 베실레이트 염
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
HUE036408T2 (hu) 2011-03-14 2018-07-30 Boehringer Ingelheim Int A leukotrién-termelés benzodioxán inhibitorai
RS63418B1 (sr) 2011-06-10 2022-08-31 Merck Patent Gmbh Kompozicije i metode za proizvodnju jedinjenja pirimidina i piridina sa btk inhibitorskom aktivnošću
JP5987220B2 (ja) 2011-07-19 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエンａ４ヒドロラーゼの阻害剤としてのアリールピラゾールエーテル
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
CA2857150C (en) 2011-11-29 2019-04-09 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
MX2014010563A (es) 2012-03-06 2014-12-05 Boehringer Ingelheim Int Benzodioxanos en combinacion con otros activos para inhibir la produccion de leucotrieno.
AR091315A1 (es) 2012-03-06 2015-01-28 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
JP6256467B2 (ja) 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
HUE044146T2 (hu) 2012-09-10 2019-09-30 Principia Biopharma Inc Pirazolopirimidin vegyületek mint kináz inhibitorok
JP6402115B2 (ja) 2013-02-04 2018-10-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
RU2696559C2 (ru) 2013-03-14 2019-08-05 Селтакссис, Инк. Ингибиторы лейкотриен а4-гидролазы
MX367918B (es) 2013-04-25 2019-09-11 Beigene Ltd Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
EP3022193B1 (en) 2013-07-15 2017-04-26 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
JP2016523982A (ja) 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EA201691169A1 (ru) 2013-12-05 2016-09-30 Асерта Фарма Б.В. Терапевтическая комбинация ингибитора pi3k и ингибитора btk
UA117498C2 (uk) 2013-12-20 2018-08-10 Новартіс Аг Гетероарильні похідні бутанової кислоти як інгібітори lta4h
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
MY188048A (en) 2014-10-24 2021-11-12 Bristol Myers Squibb Co Indole carboxamide compounds useful as kinase inhibitors
KR102602947B1 (ko) 2014-11-03 2023-11-16 아이오메트 파마 엘티디 제약 화합물
CN107001368B (zh) 2014-11-21 2019-05-31 埃斯特韦制药股份公司 具有多重模式抗疼痛活性的1,9-二氮杂螺环十一烷化合物
CN107427468B (zh) 2014-12-24 2022-02-25 普林斯匹亚生物制药公司 Btk抑制剂的部位特异性给药
GB201507753D0 (en) * 2015-05-06 2015-06-17 Biolipox Ab New compounds and uses
KR102666352B1 (ko) 2015-06-03 2024-05-17 프린시피아 바이오파마, 인코퍼레이티드 티로신 키나제 억제제
EP3307732A1 (en) 2015-06-10 2018-04-18 Biogen MA Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
SG11201802927VA (en) 2015-11-04 2018-05-30 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
PL3372607T3 (pl) 2016-01-05 2021-09-20 Jiangsu Hengrui Medicine Co. Ltd. Postać krystaliczna inhibitora kinazy btk i sposób jego otrzymywania
CA3028169A1 (en) 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
JP7545570B2 (ja) * 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用

Also Published As

Publication number Publication date
CR20230125A (es) 2023-05-11
ECSP23017158A (es) 2023-04-28
CN116157404A (zh) 2023-05-23
US20220048909A1 (en) 2022-02-17
EP4196478A1 (en) 2023-06-21
AR123241A1 (es) 2022-11-09
TW202220990A (zh) 2022-06-01
SA523442503B1 (ar) 2024-07-31
CL2023000418A1 (es) 2023-09-29
JP2023537357A (ja) 2023-08-31
KR20230051227A (ko) 2023-04-17
BR112023002031A2 (pt) 2023-03-07
JP7545570B2 (ja) 2024-09-04
AU2021325431B2 (en) 2024-01-18
JP2024123025A (ja) 2024-09-10
AU2024200054A1 (en) 2024-01-25
AU2021325431A1 (en) 2023-01-19
PE20230855A1 (es) 2023-05-29
US11708366B2 (en) 2023-07-25
CO2023002940A2 (es) 2023-03-17
UY39377A (es) 2022-03-31
CA3185469A1 (en) 2022-02-17
US20240043425A1 (en) 2024-02-08
IL299091A (en) 2023-02-01
MX2023001725A (es) 2023-02-22
WO2022034529A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
ECSP23017158A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
PA8591701A1 (es) Derivados de pirrolopirimidina
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
AR125594A1 (es) Moduladores alostéricos negativos novedosos de ciclopenta[c]pirrol de nr2b
EA202192111A1 (ru) Новые тритерпеновые производные в качестве ингибиторов вич
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
UY39722A (es) Nuevos derivados de heteroaril aminopropanol
AR130303A1 (es) Compuestos de pirazolilsulfonamida y su uso terapéutico
AR124982A1 (es) Macrociclos y sus usos
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
AR124136A1 (es) Nuevos compuestos orgánicos
AR129367A1 (es) Derivados de pirazol como agonistas de sting
AR126834A1 (es) Profármacos y derivados de psilocina y usos de estos
AR128879A1 (es) DERIVADOS DE PIRIDO-[3,4-d]PIRIDAZINA AMINA ÚTILES COMO DERIVADOS DE NLRP3
AR129798A1 (es) Compuestos de cd73